The bear case carries stronger weight on structural issues determining 12-month returns. The $93.5B cash position is not retained earnings but proceeds from an $85.7B equity issuance that increased share count from 10.6B to 13.2B (~24% dilution), and with $19.2B/quarter capex, cash runway is ~5 quarters—making SPCX MORE dependent on capital markets now than before the raise. The 85x forward P/E on negative TTM EPS of -$1.09 and -35.66% net margin is extreme. Morgan Stanley's $300 case attributes $165 (55%) to an orbital AI compute TAM with only a Google TPU test partnership as evidence. Hostile macro (10Y at 2007 highs, 30Y at 2004 highs, 97% probability of no 2026 Fed cuts) and late-cycle euphoria positioning (JPMorgan #4 "most hyped," WSB maximalists, death cross in effect) create multiple compression risk. Q2 2026 operating loss worsened, not improved, after stripping Q1 non-operating charge. The expected-value math of -5.7% over 12 months at $148 is more honest than the bull's 4:1 framing. The bear's strongest counter to the bull's lockup absorption point: subsequent price action drifted -3.1% on normal volume, and "absorption" requires price to rally off forced supply, which it didn't.

POSITION STRATEGY: TRIM existing long exposure aggressively—target cutting position size by 50-70% from current levels. The valuation regime (85x forward P/E, negative TTM EPS) does not reward holding through a hostile macro tape.

SELL RALLIES: Sell rallies into the $153-$160 zone if they materialize. This corresponds to the 10 EMA ($149.87), the upper Bollinger band, and the post-lockup resistance area. The 200 SMA at $143.23 is overhead supply, not support, on any retest from below. Use limit orders, not market orders.

AVOID NEW POSITIONS: Avoid initiating any new long position at current levels ($148 area). The setup requires either (a) a meaningful flush to $115-$130 to retest the August base, or (b) a fundamental re-rating that addresses the dilution-financed cash runway. Neither condition is met today.

STOP LOSSES: Tighten stops on any remaining long exposure to $143 (the 200 SMA). A close below $143 on expanding volume would confirm the death cross and likely trigger a re-test of the August low zone ($108-115). Don't fight that tape.

KEY LEVELS: Resistance: $149.87 (10 EMA), $153-155 (post-lockup supply zone), $157 (technical breakout trigger). Support: $143.23 (200 SMA—critical), $135.57 (50 SMA), $125-130 (next major support), $108-115 (August base/flush zone). Trigger to flip constructive: a daily close above $157 with volume >120M shares AND the 50 SMA crossing back above the 200 SMA.

CATALYSTS TO WATCH: Q3 2026 earnings (likely October/November): watch for revenue beat vs. consensus, FCF commentary, and any disclosure on Starship/Starlink unit economics. Google TPU-in-orbit progression: any movement from 'test partnership' to 'multi-year revenue contract' materially de-risks the AI thesis; absence by year-end is bearish. Starship milestones: each successful orbital test re-rates launch economics; failures compress the TAM. Lockup wave 2 timing: monitor for additional employee RSU and insider unlock windows over the next 6-12 months. Fed policy: any surprise dovish pivot (cuts in 2026) would support multiple expansion; current Polymarket pricing implies this is unlikely. Trump-Xi summit outcomes: watch for satellite/AI export control language as a tail risk.

POSITION SIZING: If SPCX flushes to $115-130 on a broader tech de-rate with business fundamentals intact (revenue still growing >50% YoY, EBITDA still positive, no Starship/Starlink disruption), that's the zone to begin a scaled-in long with tight risk. Target re-entry size of 30-50% of the position you just trimmed, with stops below $108.

RISK MANAGEMENT: Avoid averaging down into a falling knife at current levels. The bull case requires multiple positive surprises in sequence (Q3 beat, Google contract, Starship success) to validate the 85x forward multiple. The probability of all three landing cleanly in a hostile macro is low. Discipline beats conviction here.

The Underweight recommendation is anchored in a structurally unfavorable equity setup at $148: 85x forward P/E on negative TTM EPS with a -35.66% net margin, combined with a dilution-financed cash runway (~5 quarters at current capex burn) that leaves SPCX MORE dependent on capital markets than before the $85.7B raise — not less. The bear's dilution math effectively dismantled the bull's "fortress balance sheet" thesis by reframing the $93.5B cash position as the proceeds of an ~24% share count expansion (10.6B → 13.2B), not retained earnings. With a hostile macro tape (10Y at 2007 highs, 30Y at 2004 highs, 97% probability of no 2026 Fed cuts, active Trump-Xi export-control tail risk), a multiple-compression regime is more probable than further expansion. Crowded long positioning (JPMorgan #4 most hyped, WSB leverage maximalists, President Shotwell filing $52M in 10b5-1 sales) and a slow-motion death cross (50 SMA still well below 200 SMA at $143.23) reinforce the negative skew. I'm choosing Sell rather than Hold to execute the plan's directive: trim existing exposure 50-70%, sell rallies into the $153-$160 zone (10 EMA, upper Bollinger, post-lockup supply), and avoid averaging down at current levels. The business isn't broken — revenue growth, EBITDA inflection, and Starlink dominance are real — which is why this is an Underweight/trim rather than full exit; a flush to $115-130 or a fundamental re-rating of the cash runway question would be the conditions to reassess.

Stop loss: $157.00

Sizing: Trim 50-70% of existing long exposure; sell rallies into $153-$160 zone. If price fails to reach $153, scale out 25% at $149.87 (10 EMA), another 25% at $153, final 25-50% on any extension to $157-160. Avoid initiating any new long position until either a flush to $115-130 or a fundamental re-rating addresses the dilution-financed cash runway. Remaining core position (if any) should carry a hard stop at $143 (200 SMA close, not intraday).